<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01511471</url>
  </required_header>
  <id_info>
    <org_study_id>PATRASCARDIOLOGY-9</org_study_id>
    <nct_id>NCT01511471</nct_id>
  </id_info>
  <brief_title>Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis</brief_title>
  <official_title>Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Patras</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clopidogrel administration is commonly prescribed in patients undergoing percutaneous
      coronary intervention, in patients with previous stroke and in patients under chronic
      hemodialysis via fistulae. Patients with chronic renal failure present lower clopidogrel
      response compared to those with normal renal function. Ticagrelor is a new oral direct-acting
      antagonist, which provides greater platelet inhibition in both clopidogrel responders and
      non-responders. It has also been shown that in patients with chronic kidney disease
      (creatinine clearance &lt;60 mL/min)ticagrelor achieved an absolute risk reduction of
      cardiovascular death, myocardial infarction, and stroke greater than that of patients with
      normal renal function. Clopidogrel resistant patients as assessed by VerifyNow
      P2Y12(Accumetrics)will be administered after informed consent ticagrelor 90 mg twice daily
      for 15 days. Platelet reactivity will be determined at the end of the treatment period.
      Bleeding events, major adverse cardiac events and any side effects until Day 15 will be
      reported in a descriptive manner.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet reactivity assessed by VerifyNow P2Y12 assay</measure>
    <time_frame>Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding events according to TIMI criteria</measure>
    <time_frame>Day 15</time_frame>
    <description>Major, minor or minimal bleeding events according to TIMI criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>Day 15</time_frame>
    <description>Death, non-fatal myocardial infarction and stroke</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Platelet Reactivity</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor 90mg twice a day for 15 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor 90mg twice a day for 15 days</description>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age≥18 years

          -  Chronic renal failure under haemodialysis

          -  Platelet reactivity under clopidogrel 75mgx1 ≥235 PRU

          -  Informed written consent

        Exclusion Criteria:

          -  Recent (within 1 month) PCI or ACS

          -  Requirement for oral anticoagulant prior to the Day 14 visit

          -  PLTs&lt;100.000 / μL), Hct &lt;28%, Hct &gt; 52% at randomization

          -  Increased risk of bradycardiac events.

          -  Severe uncontrolled chronic obstructive pulmonary disease

          -  Known severe hepatic impairment

          -  History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal
             bleeding within the previous 6 months.

          -  Other bleeding diathesis, or considered by investigator to be at high risk for
             bleeding

          -  Concomitant therapy with a strong cytochrome P-450 3A inhibitor or inducer

          -  Recent (&lt;6weeks)major surgery including CABG

          -  Recent (&lt;6weeks)stroke or any prior intracranial bleeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Agios Andreas General Hospital, Nephrology Department</name>
      <address>
        <city>Patras</city>
        <state>Achaia</state>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Department Patras University Hospital</name>
      <address>
        <city>Rio</city>
        <state>Achaia</state>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2012</study_first_submitted>
  <study_first_submitted_qc>January 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2012</study_first_posted>
  <last_update_submitted>February 2, 2012</last_update_submitted>
  <last_update_submitted_qc>February 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Patras</investigator_affiliation>
    <investigator_full_name>Dimitrios Alexopoulos</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Ticagrelor</keyword>
  <keyword>platelet reactivity</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>haemodialysis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

